Key Metrics
CiteScore 

0.8
H-Index 

20
Impact Factor 

< 5
SJR 

Q3Pharmacology

SNIP 

0.48
Recommended pre-submission checks
Powered by 

Medical Letter on Drugs and Therapeutics Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | MED LETTER INC |
| Language | English |
| Frequency | Fortnightly |
| General Details |
View less
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers in Medical Letter on Drugs and Therapeutics
Ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
Omidenepag isopropyl (Omlonti) for glaucoma.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
Sonrotoclax (Beqalzi) for mantle cell lymphoma.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
Vepdegestrant (Veppanu) for advanced breast cancer.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
In brief: New warning for OTC orlistat (Alli).
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
OTC Differin Epiduo gel for acne.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
Ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
Omidenepag isopropyl (Omlonti) for glaucoma.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
Sonrotoclax (Beqalzi) for mantle cell lymphoma.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
Vepdegestrant (Veppanu) for advanced breast cancer.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
In brief: New warning for OTC orlistat (Alli).
- 20 Jul 2026
- The Medical letter on drugs and therapeutics
OTC Differin Epiduo gel for acne.
- 20 Jul 2026
- The Medical letter on drugs and therapeutics